bioAffinity Technologies, Inc. ( (BIAF) ) just unveiled an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
bioAffinity Technologies, Inc. reports a successful year in 2024, significantly boosting sales and operations through its lung cancer detection product, CyPath Lung. The company plans to expand its market presence in 2025, leveraging its growth in the U.S. healthcare system and focusing on key regions and markets, including the VA and military sectors, to further increase the accessibility and adoption of its test.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. operates in the medical diagnostics industry, focusing on the early detection of lung cancer through its noninvasive test, CyPath Lung. The company aims to address the critical need for early cancer detection, holding patents in the U.S., the European Union, and Asia, with a significant market presence in these regions.
YTD Price Performance: -19.73%
Average Trading Volume: 140,230
Technical Sentiment Consensus Rating: Buy
See more data about BIAF stock on TipRanks’ Stock Analysis page.
